[CORVITA LETTERHEAD]



                                                                  April 17, 1996

Dear Shareholders:

     On behalf of the Board of Directors of Corvita Corporation (the "Company"),
I am pleased to inform you that on April 11, 1996, the Company entered into a
definitive Agreement and Plan of Merger (the "Merger Agreement") with Pfizer
Inc. ("Pfizer"), and a wholly-owned subsidiary of Pfizer ("HPG"), pursuant to
which Pfizer has agreed to acquire the Company in a two-step transaction.

     On April 17, 1996, pursuant to the Merger Agreement, HPG commenced a cash
tender offer for any and all outstanding shares of the Company's common stock at
a price of $10.25 per share net to the seller in cash (the "Offer"). Following
successful completion of the Offer, it is expected that HPG will be merged with
and into the Company, with the Company surviving the merger (the "Merger"). At
the effective time of the Merger, each share of common stock issued and
outstanding (other than shares of common stock held by Pfizer, HPG or the
Company, or by a subsidiary of Pfizer or the Company) will be converted into the
right to receive $10.25 per share in cash or any greater amount paid pursuant to
the Offer, without interest.

     YOUR BOARD OF DIRECTORS, BY THE UNANIMOUS VOTE OF ALL OF THE DIRECTORS OF
THE COMPANY, APPROVED THE OFFER AND THE MERGER IN ALL RESPECTS AND DETERMINED
THAT THE TERMS OF THE OFFER AND THE MERGER ARE FAIR TO, AND IN THE BEST
INTERESTS OF, THE SHAREHOLDERS OF THE COMPANY AND RECOMMENDS THAT SHAREHOLDERS
OF THE COMPANY ACCEPT THE OFFER AND TENDER THEIR SHARES.

     In reaching its conclusions, the Board of Directors gave careful
consideration to a number of factors, which are described in the Schedule 14D-9
filed by the Company with the Securities and Exchange Commission and enclosed
with this letter. The Board also engaged Dillon, Read & Co. Inc. as its
financial advisor to evaluate the Offer and the Merger, and Dillon, Read & Co.,
Inc. has rendered to the Board its opinion, which is included as an exhibit to
the Schedule 14D-9, that the cash consideration to be received by the Company's
shareholders is fair from a financial point of view to such shareholders as of
the date of delivery of such opinion.

     The enclosed Offer to Purchase and related Letter of Transmittal set forth,
in detail, the terms and conditions of the Offer and provide instructions on how
to tender your shares. I urge you to read the enclosed materials carefully.

                                        Sincerely,



                                        /s/ Norman R. Weldon, Ph.D.
                                        -------------------------------------
                                        Norman R. Weldon, Ph.D.
                                        President and Chief Executive Officer